Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of CTI-1601 for the treatment of Friedreich's Ataxia.

Trial Profile

A study of CTI-1601 for the treatment of Friedreich's Ataxia.

Phase of Trial: Phase I

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs CTI 1601 (Primary)
  • Indications Friedreich's ataxia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Feb 2017 New trial record
    • 06 Feb 2017 According to a Chondrial Therapeutics media release, company is planning to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) and after acceptance of the IND, company will initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top